drugset / Trial / NCT04583020
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
Phase 2
Unknown
42 enrolled
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to study the safety and efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas.
Timeline
- Start
- 2020-11-12
- Primary completion
- 2023-12-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |